You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Advancing a Glioma Immunotherapy

    SBC: IN CYTU, INC.            Topic: 102

    DESCRIPTION provided by applicant A Phase II SBIR program of preclinical development is proposed for the development of an active specific immunotherapeutic called Cellariumandquot for treatment of glial cell based cancers Successful completion of this project will confirm therapeutic effect and pre clinical safety of the vaccine in preparation for first in human studies Upon demonstration of ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma

    SBC: L2 DIAGNOSTICS LLC            Topic: 102

    DESCRIPTION provided by applicant Hepatocellular carcinoma HCC is the most prevalent cancer in human population and will lead to over deaths in the United States this year alone However the molecular mechanisms driving hepatocellular carcinoma HCC growth and metastasis remain elusive and there is a huge unmet medical need to find new therapeutic targets We performed an unbiased ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Simultaneous kinetic analyses of neuronal connectivities

    SBC: CIENCIA INC            Topic: 101

    DESCRIPTION provided by applicant Aberrant neuronal connectivity is associated with a number of neuropathological and neuropsychiatric diseases disorders Inefficient developmental connectivity misdirected connectivity or disrupted and degenerated connectivity can account for losses of normal neuronal communication and subsequent losses of mental or physical health Altered expression of axon ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid Detection of Multiple Drug resistant TB from Sputum

    SBC: TANGEN BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Tuberculosis TB is a leading cause of mortality from an infectious disease in the world second only to HIV AIDS The WHO reports that in there were M deaths from TB When a case of TB does not respond to two or more of the first line drugs available the infection is considered to be multidrug resistant MDR TB The rising incidence of MDR TB is lea ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Non adjuvanted VLP Vaccine against Stealth H N Influenza

    SBC: EPIVAX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic Neutralizing antibodies are not detected in acute phase infection Anti H antibody responses are significantly delayed and exhibit low avidity in comparison with antibodies generated following seas ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Trypanocidal Compounds for the Treatment of Stage and HAT

    SBC: MEDISYNERGICS, LLC            Topic: R

    DESCRIPTION provided by applicant Human African Trypanosomiasis HAT is a disease caused by a parasitic organism trypanosoma brucei It is often referred to as andquot sleeping sicknessandquot because of the symptoms that emerge in Stage patients The disease exists in two forms depending on the causative parasite Trypanosoma brucei gambiense or Trypanosoma brucei rhodesiense T b gamb ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Routinizing HIV testing for Adolescents

    SBC: MEDIA REZ LLC            Topic: NICHD

    DESCRIPTION provided by applicant This study will aim to assess the feasibility and acceptability of using state of the art social media and game technology to increase HIV testing among adolescents and young adults AYA ages Rates of HIV testing among AYA are low resulting in high proportions of AYA who are positive or unaware of their HIV infection Further public health messages wh ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. SMALL MOLECULE THERAPY FOR ALZHEIMER'S DISEASE

    SBC: Recombinant Technologies LLC            Topic: NIA

    DESCRIPTIONprovided by applicantAlzheimer s diseaseADrepresents a progressive degenerative illness that affects the brainresulting in memory impairmentThe complex etiology of AD is not fully resolvedalthough toxic isoforms of amyloidAplaques are strongly implicatedCurrent treatment options are considered to be symptomaticThey are only moderately effective in stabilizing or improving cognitive and ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government